Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Hypertrophic cardiomyopathy (HCM) is mainly caused by sarcomeric mutations which may affect myocardial mechano-energetic efficiency (MEE). We investigated the effects of sarcomeric mutations on MEE. A non-invasive pressure/volume (P/V) analysis was performed. We included 49 genetically screened HCM patients. MEEi was calculated as the ratio between stroke volume and heart rate normalized by LV mass. Fifty-seven percent (57%) HCM patients carried a sarcomeric mutation. Patients with and without sarcomeric mutations had similar LV ejection fraction, heart rate, LV mass, and LV outflow gradient. Younger age at diagnosis, family history of HCM, and lower MEEi were associated with presence of sarcomeric mutation (p = 0.017; p = 0.001 and p = 0.0001, respectively). Lower MEEi in HCM with sarcomeric mutation is not related to significant differences on filling pressure as shown on P/V analysis. Sarcomeric mutations determine a reduction of the LV pump performance as estimated by MEEi in HCM. Lower MEEi may predict a positive genetic analysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12265-023-10441-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dilated Cardiomyopathy - Exploring the Underlying Causes.
Med Res Arch
December 2024
Department of Molecular and Cellular Biosciences, University of Cincinnati College of Medicine, 231 Albert Sabin Way.
Cardiovascular disease is one of the world's leading causes of natural mortality, taking approximately 18 million lives each year. Dilated cardiomyopathy, a subgroup of cardiac diseases, has an annual incidence of 5 - 8 cases per 100,000 for European and North American populations. Common features of dilated cardiomyopathy include cardiac chamber enlargement, impaired systolic function, reduced ejection fraction, and arrhythmias, with an endpoint of ventricular dilation and heart failure.
View Article and Find Full Text PDFHyperpolarized-MRI in Hypertrophic Cardiomyopathy: A Narrative Review.
Clin Med Insights Cardiol
August 2025
Mount Sinai Fuster Heart Hospital, Icahn School of Medicine, New York, NY, USA.
Hypertrophic cardiomyopathy is a genetically inherited cardiac disorder that presents with diverse clinical phenotypes. It is associated with significant adverse outcomes, including arrhythmias and sudden cardiac death. Current gold-standard diagnostic methods include echocardiography and cardiac magnetic resonance imaging.
View Article and Find Full Text PDFTranslational Control in Cardiac Pathophysiology and Therapeutic Development: When mRNA Meets the Heart.
Int J Mol Sci
August 2025
Aab Cardiovascular Research Institute, Department of Medicine, University of Rochester School of Medicine & Dentistry, Rochester, NY 14586, USA.
Cardiac physiology and pathology have been extensively explored at the transcriptional level. Still, they are less understood at the translational level, including three major knowledge gaps: pathophysiological impact, molecular mechanisms, and therapeutic implications of translational control in cardiac biology and heart disease. This review aims to provide a summary of the most recent key findings in this emerging field of translational control in heart health and disease, covering the physiological functions, disease pathogenesis, biochemical mechanisms, and development of potential RNA-based, translation-manipulating drugs.
View Article and Find Full Text PDFManagement of Malignant Arrhythmia in Apical Hypertrophic Cardiomyopathy: A Case Report.
Am J Case Rep
August 2025
Department of Cardiovascular Medicine, Center of the Heart, El Paso, TX, USA.
BACKGROUND Apical hypertrophic cardiomyopathy (ApHCM) is a rare variant that is less frequently associated with sarcomere mutations and lacks specific diagnosis and risk stratification guidelines. CASE REPORT We present the case of a 41-year-old man with a complex medical history, including type I diabetes mellitus and alcohol use disorder, who presented with nausea and vomiting following alcohol consumption. Initial evaluations revealed significant electrolyte imbalances and non-sustained ventricular tachycardia (NSVT).
View Article and Find Full Text PDFRBPMS and RBPMS2 Cooperate to Safeguard Cardiac Splicing.
Circ Res
August 2025
Department of Medicine, University of California San Diego, La Jolla (Z.C., Z.Z., Y.G., X.Z., J.C.).
Background: Mutations in cardiac SFs (splicing factors) cause cardiomyopathy and congenital heart disease, underscoring the critical role of SFs in cardiac development and disease. Cardiac SFs are implicated to cooperatively regulate the splicing of essential cardiac genes, but the functional importance of their collaboration remains unclear. RBPMS (RNA-binding protein with multiple splicing) and RBPMS2 (RNA-binding protein with multiple splicing 2) are SFs involved in heart development and exhibit similar splicing regulatory activities in vitro, but it is unknown whether they cooperate to regulate splicing in vivo.
View Article and Find Full Text PDF